LINC01556: A Non-Coding RNA Molecule as A Potential Drug Target for Cancer

Target Name: LINC01556

NCBI ID: G729583

LINC01556

Other Name(s): C6orf100 | long intergenic non-protein coding RNA 1556 | dJ25J6.5 | Long intergenic non-protein coding RNA 1556

LINC01556: A Non-Coding RNA Molecule as A Potential Drug Target for Cancer

LINC01556 is a non-coding RNA molecule that has been identified as a potential drug target (or biomarker) for the treatment of various diseases, including cancer. Its unique structure and expression patterns have made it an attractive target for researchers to study, and recent studies have shed light on its potential role in the development and progression of these diseases.

LINC01556 is a small non-coding RNA molecule that is known for its ability to interact with various proteins, including the transcription factor, p53. The p53 is a well-known protein that plays a crucial role in regulating gene expression and has been implicated in the development of many diseases, including cancer. By interacting with p53, LINC01556 has been shown to regulate its activity and contribute to the regulation of gene expression.

One of the key features of LINC01556 is its structure. It is a small molecule that has a length of approximately 200 nucleotides and a 26-nt stem-loop region in the middle. The stem-loop region is a common structural motif that is found in many non-coding RNAs and has been shown to play a role in their stability and function. The unique 26-nt stem-loop region of LINC01556 has been shown to be important for its interaction with p53 and for its role in regulating gene expression.

Another feature of LINC01556 is its expression patterns. It is expressed in various tissues and organs, including the brain, heart, and gastrointestinal tract. Its expression patterns have been shown to be regulated by various factors, including the cell cycle, apoptosis, and inflammation. The regulation of LINC01556 expression by these factors has implications for its potential as a drug target and biomarker.

In addition to its structural and expression patterns, LINC01556 has also been shown to play a role in the regulation of cellular processes. It has been shown to interact with various proteins, including the transcription factor, activator protein 1 (AP-1), and Ku70. The interaction between LINC01556 and AP-1 has implications for its potential as a drug target for the treatment of cancer.

The potential drug target status of LINC01556 is supported by several recent studies. In one study, researchers found that LINC01556 was a significant positive predictor of cancer grade in human breast tissue samples. In another study, researchers found that LINC01556 was a significant positive predictor of the survival rate in patients with colorectal cancer. These findings suggest that LINC01556 may be a useful biomarker for the diagnosis and treatment of cancer.

In conclusion, LINC01556 is a non-coding RNA molecule that has been identified as a potential drug target (or biomarker) for the treatment of various diseases, including cancer. Its unique structure and expression patterns have made it an attractive target for researchers to study, and recent studies have shed light on its potential role in the development and progression of these diseases. Further research is needed to fully understand the potential of LINC01556 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1556

The "LINC01556 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01556 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets